Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Dovato in HIV-1 Patients on Opioid Agonist Therapy
NCT06580873Phase 4Not yet recruiting
- Sponsor
- Saskatchewan Health Authority
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Saskatchewan Health Authority. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06580873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580873.